tetano
Editor, Senior Moderator
J Cardiovasc Med (Hagerstown)
. 2022 Jan 10.
doi: 10.2459/JCM.0000000000001297. Online ahead of print.
Echocardiographic systolic pulmonary arterial pressure and mortality in coronavirus disease 2019 patients
Marco Zuin[SUP] 1 [/SUP], Loris Roncon, Giovanni Zuliani
Affiliations
Abstract
Aims: We perfromed a systematic review and meta-analysis to compare the echocardiographic systolic pulmonary arterial pressure (sPAP) difference between COVID-19 survivors (S) and nonsurvivors (NS).
Methods: MEDLINE and Scopus databases were systematically searched for articles, published in English language, from inception through 15 May 2021 using the following Medical Subject Heading (MESH) terms: COVID-19 [Title/Abstract] AND pulmonary arterial pressure [Title/Abstract] OR Echocardiography [Title/Abstract]. The difference of sPAP measurement obtained at transthoracic echocardiography between nonsurvivors and survivors was expressed as mean difference with the corresponding 95% confidence interval (CI) using a random-effect model.
Results: Nine studies, enrolling 788 patients (mean age 62.8 years old, 479 ,men) met the inclusion criteria and were included into the analysis.Using a randomeffect mode, sPAP was 11.8mmHg (95% CI, 6.60-16.97; P<0.0001, I2=89.3%) higher in NS compared with S. Sensitivity analysis confirmed yielded results.
Conclusions: COVID-19 NS had a higher sPAP compared with S, reinforcing previous observations demonstrating the critical role of RV function in determining the short-term outcome of COVID-19 patients.
. 2022 Jan 10.
doi: 10.2459/JCM.0000000000001297. Online ahead of print.
Echocardiographic systolic pulmonary arterial pressure and mortality in coronavirus disease 2019 patients
Marco Zuin[SUP] 1 [/SUP], Loris Roncon, Giovanni Zuliani
Affiliations
- PMID: 35013053
- DOI: 10.2459/JCM.0000000000001297
Abstract
Aims: We perfromed a systematic review and meta-analysis to compare the echocardiographic systolic pulmonary arterial pressure (sPAP) difference between COVID-19 survivors (S) and nonsurvivors (NS).
Methods: MEDLINE and Scopus databases were systematically searched for articles, published in English language, from inception through 15 May 2021 using the following Medical Subject Heading (MESH) terms: COVID-19 [Title/Abstract] AND pulmonary arterial pressure [Title/Abstract] OR Echocardiography [Title/Abstract]. The difference of sPAP measurement obtained at transthoracic echocardiography between nonsurvivors and survivors was expressed as mean difference with the corresponding 95% confidence interval (CI) using a random-effect model.
Results: Nine studies, enrolling 788 patients (mean age 62.8 years old, 479 ,men) met the inclusion criteria and were included into the analysis.Using a randomeffect mode, sPAP was 11.8mmHg (95% CI, 6.60-16.97; P<0.0001, I2=89.3%) higher in NS compared with S. Sensitivity analysis confirmed yielded results.
Conclusions: COVID-19 NS had a higher sPAP compared with S, reinforcing previous observations demonstrating the critical role of RV function in determining the short-term outcome of COVID-19 patients.